# A Dose-finding Study of OPC-6535 in Patients With Active Ulcerative Colitis

> **NCT00317356** · PHASE2 · TERMINATED · sponsor: **Otsuka Pharmaceutical Co., Ltd.** · enrollment: 43 (actual)

## Conditions studied

- Colitis, Ulcerative

## Interventions

- **DRUG:** OPC-6535(Tetomilast)

## Key facts

- **NCT ID:** NCT00317356
- **Lead sponsor:** Otsuka Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-05
- **Primary completion:** 2007-08
- **Final completion:** 2007-08
- **Target enrollment:** 43 (ACTUAL)
- **Why stopped:** Efficacy was not cleared at US study
- **Last updated:** 2021-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00317356

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00317356, "A Dose-finding Study of OPC-6535 in Patients With Active Ulcerative Colitis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00317356. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*